Zenas BioPharma (NASDAQ:ZBIO) Cut to “Strong Sell” at Wall Street Zen

Zenas BioPharma (NASDAQ:ZBIO) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “strong sell” rating in a report released on Saturday.

Several other equities analysts also recently commented on ZBIO. Evercore assumed coverage on shares of Zenas BioPharma in a report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 price target on the stock. Guggenheim upped their target price on Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Monday, December 29th. Morgan Stanley boosted their price objective on Zenas BioPharma from $19.00 to $21.00 and gave the company an “equal weight” rating in a report on Tuesday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $48.00 price objective on shares of Zenas BioPharma in a research report on Tuesday, January 6th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $44.14.

Zenas BioPharma Stock Performance

NASDAQ:ZBIO opened at $22.30 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 5.66 and a current ratio of 5.61. The stock’s fifty day moving average is $23.17 and its 200 day moving average is $27.16. The firm has a market capitalization of $1.28 billion, a PE ratio of -2.86 and a beta of -1.94. Zenas BioPharma has a fifty-two week low of $6.11 and a fifty-two week high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings data on Monday, March 16th. The company reported ($4.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by ($3.32).

Insider Buying and Selling

In other news, CEO Leon O. Moulder, Jr. acquired 57,000 shares of Zenas BioPharma stock in a transaction on Monday, February 2nd. The shares were bought at an average cost of $17.96 per share, for a total transaction of $1,023,720.00. Following the acquisition, the chief executive officer directly owned 423,155 shares of the company’s stock, valued at $7,599,863.80. This trade represents a 15.57% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Patricia L. Allen bought 15,700 shares of the firm’s stock in a transaction on Thursday, February 12th. The shares were purchased at an average cost of $24.85 per share, with a total value of $390,145.00. Following the completion of the transaction, the director owned 15,700 shares in the company, valued at $390,145. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 202,845 shares of company stock valued at $3,747,185 over the last quarter. 16.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZBIO. Federated Hermes Inc. grew its position in shares of Zenas BioPharma by 60.8% in the 2nd quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock worth $18,041,000 after buying an additional 703,838 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Zenas BioPharma by 41.2% in the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock valued at $89,000 after acquiring an additional 2,679 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Zenas BioPharma by 120.0% in the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after purchasing an additional 1,716 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in Zenas BioPharma in the third quarter worth $30,000. Finally, Quarry LP increased its position in shares of Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after purchasing an additional 291 shares in the last quarter.

More Zenas BioPharma News

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $44 price target for Zenas BioPharma, a reaffirmation that can support longer-term investor interest despite other negative headlines. HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO)
• Neutral Sentiment: HC Wainwright published detailed forward EPS models (FY2026–FY2030) outlining updated multi‑year loss assumptions; these give investors a clearer roadmap for expected cash burn and timeline to potential improvement but are forecasts rather than company actions. ZBIO analyst estimates (MarketBeat)
• Negative Sentiment: Zacks downgraded Zenas BioPharma from “hold” to “strong sell,” a headline that can accelerate outflows from more conservative holders. Zacks.com
• Negative Sentiment: HC Wainwright cut near‑term EPS estimates across multiple quarters and fiscal years (Q1–Q4 2026 and FY2026–FY2029), materially widening projected losses for 2026–2028 versus prior forecasts; earnings downgrades typically pressure shares as they reduce near‑term visibility into profitability. ZBIO analyst estimates (MarketBeat)
• Negative Sentiment: Recent posted quarterly results showed a large EPS miss, reinforcing analyst downgrades and increasing near‑term uncertainty around execution and cash needs. ZBIO company/earnings information (MarketBeat)

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.